Is AYTU or BIOA more undervalued in 2026?

CirclFi compares Aytu BioPharma, Inc. (AYTU) and BioAge Labs, Inc. (BIOA) using 13 institutional-grade valuation models. AYTU has a Quality of Company score of 6.0/10 while BIOA scores 5.1/10.

Which is a better buy — AYTU or BIOA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AYTU and BIOA valuations compare?

AYTU at $2.24 and BIOA at $17.05 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AYTU vs BIOA Valuation Comparison 2026 — Intrinsic Value Analysis

AYTU

Drug Manufacturers - Specialty & Generic

Aytu BioPharma, Inc.

Quality

6.0

out of 10

Value Trap

SAFE

Price

$2.24

Last close

Models

12/13

Active

BIOA

Drug Manufacturers - Specialty & Generic

BioAge Labs, Inc.

Quality

5.1

out of 10

Value Trap

SAFE

Price

$17.05

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	AYTU Fair Value	AYTU Upside	BIOA Fair Value	BIOA Upside
Bayesian DCF	Intrinsic	$2.21	-1.3%	$7.47	-56.2%
Earnings Power Value	Intrinsic	$6.38	+184.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.12	-95.4%	$1.69	-89.9%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AYTU vs BIOA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AYTU vs BIOA — Which Stock Is More Undervalued?

AYTU scores higher with a 6.0/10 quality rating vs BIOA's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aytu BioPharma, Inc. (AYTU) and BioAge Labs, Inc. (BIOA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AYTU currently trades at $2.24 with a QOC of 6.0/10, while BIOA trades at $17.05 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).